

GENOME THERAPEUTICS CORP

Form 8-K

January 09, 2004

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to**

**Section 13 or 15(d) of**

**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): January 9, 2004**

---

**GENOME THERAPEUTICS CORP.**

**(Exact name of registrant as specified in its charter)**

**Massachusetts**

**(State or other jurisdiction  
of incorporation)**

**0-10824**

**(Commission File Number)**

**04-2297484**

**(I.R.S. Employer  
Identification Number)**

**100 Beaver Street**

**Waltham, Massachusetts 02453**

**(Address of principal executive offices, including zip code)**

**(781) 398-2300**

**(Registrant's telephone number, including area code)**

---

---

Page 1 of 4 pages.

**ITEM 5. OTHER EVENTS**

On January 9, 2004, Genome Therapeutics Corp. issued a press release announcing that Genome Therapeutics and Amgen Inc. have concluded their research collaboration focused on discovering and developing therapeutics for bone diseases, which is attached hereto as Exhibit 99.1.

**Item 7. FINANCIAL STATEMENTS AND EXHIBITS.**

(c) Exhibits

99.1 Press Release issued by Genome Therapeutics Corp. on January 9, 2004.



**EXHIBIT INDEX**

**Exhibit Number**

---

**Description**

---

99.1

Press Release issued by Genome Therapeutics Corp. on January 9, 2004.